AMG 510 is the first drug to reach clinical trials that inhibits mutant KRAS proteins, which are among the most common causes of cancer. Researchers from Amgen, the company that developed the therapy, used X-ray crystallography at the Advanced Light Source to better understand the KRAS molecule. https://newscenter.lbl.gov/2019/12/23/cancer-drug-begins-clinical-trial/
January 2019 – July 2022
